The association of HIV viral load with indirect markers of liver injury

Journal of Viral Hepatitis

Volumn 19, Issue 2, 2012, Pages

  Forrester, J E ^a   Rhee, M S ^b   McGovern, B H ^c   Sterling, R K ^d   Knox, T A ^a   Terrin, N ^e  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GILEAD SCIENCES   (United States)

^c LEMUEL SHATTUCK HOSPITAL   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^e TUFTS MEDICAL CENTER   (United States)

Author keywords

FIB 4; hepatitis C; HIV; liver disease

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DIDANOSINE; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CD4 LYMPHOCYTE COUNT; DRUG ABUSE; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FUNCTION; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PRIORITY JOURNAL; THROMBOCYTE COUNT; VIRUS LOAD;

ADULT; ENZYMES; FEMALE; HEPATITIS C; HISPANIC AMERICANS; HIV; HIV INFECTIONS; HUMANS; LIVER; MALE; MIDDLE AGED; PLATELET COUNT; PROSPECTIVE STUDIES; RNA, VIRAL; VIRAL LOAD;

EID: 84855845271     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2011.01529.x     Document Type: Article

References (44)

1. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32: 492-497. (Pubitemid 32173638)
2. Konopnicki D, Mocroft A, de Wit S, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005; 19: 593-601. (Pubitemid 40543982)
3. Tatsunami S, Taki M, Shirahata A, Mimaya J, Yamada K,. Increasing incidence of critical liver disease among causes of death in Japanese hemophiliacs with HIV-1. Acta Haematol 2004; 111: 181-184. (Pubitemid 38716191)
4. Selik RM, Byers RH, Dworkin MS,. Trends in diseases reported on US death certificates that mention HIV infection, 1987-1999. J Acquir Immune Defic Syndr 2002; 29: 378-387. (Pubitemid 34288892)
5. Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166: 1632-1641. (Pubitemid 44232373)
6. Gebo KA, Diener-West M, Moore RD, et al. Hospitalization rates differ by hepatitis C status in an urban HIV cohort. J Acquir Immune Defic Syndr 2003; 34: 165-173. (Pubitemid 37248913)
7. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis c virus infection: a meta-analysis. Clin Infect Dis 2001; 33: 562-569. (Pubitemid 32709592)
8. Bonacini M, Louie S, Bzowej N, Wohl AR,. Survival in patients with HIV infection and viral hepatitis B or C: a cohort study. AIDS 2004; 18: 2039-2045. (Pubitemid 39463357)
9. Sulkowski M, Mehta SH, Torbenson MS, et al. Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS 2007; 21: 2209-2216. (Pubitemid 350287219)
10. Bruno R, Sacchi P, Puoti M, et al. Pathogenesis of liver damage in HCV-HIV patients. AIDS Rev 2008; 10: 15-24. (Pubitemid 351524048)
11. Sulkowski M,. Viral hepatitis and HIV coinfection. J Hepatol 2008; 48: 3353-3367.
12. Blackard JT, Sherman KE,. HCV/HIV co-infection: time to re-evaluate the role of HIV in the liver? J Viral Hepat 2008; 15: 323-330. (Pubitemid 351473633)
13. Vlahakis S, Villasis-Keever A, Gomez T, et al. Human immunodeficiency virus-induced apoptosis of human hepatocytes via CXCR4. J Infect Dis 2003; 188: 1455-1460. (Pubitemid 37523930)
14. Munshi N, Balasubramanian A, Koziel M, Ganju RK, Groopman JE,. Hepatitis C and human immunodeficiency virus envelope proteins cooperatively induce hepatocyte apoptosis via an innocent bystander mechanism. J Infect Dis 2003; 188: 1192-1204. (Pubitemid 37338984)
15. Hong F, Tuyama A, Lee TF, et al. Hepatic stellate cells express functional CXCR4: role in stromal cell-derived factor-1alpha-mediated stellate cell activation. Hepatology 2009; 49: 2055-2067.
16. Schmitt M, Steffan A, Gendrault J, et al. Multiplication of human immunodeficiency virus in primary cultures of human Kupffer cells-possible role of liver macrophage infection in pathophysiology of AIDS. Res Virol 1990; 141: 143-152. (Pubitemid 20147081)
17. Steffan A, Lafon M, Gendrult J, et al. Primary cultures of endothelial cells from the human liver sinusoid are permissive for human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1992; 89: 1582-1586.
18. Brau N, Salvatore M, Rios-Bedoya CF, et al. Slower fibrosis progression in HIV/HCV-co-infected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006; 44: 47-55. (Pubitemid 41772515)
19. Mehta SH, Thomas DL, Torbenson M, et al. The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis coinfection. Hepatology 2005; 41: 123-131. (Pubitemid 40066390)
20. Sterling RK, Chiu S, Snider K, Nixon D,. The prevalence and risk factors for abnormal liver enzymes in HIV-positive patients without hepatitis B or C co-infections. Dig Dis Sci 2008; 53: 1375-1382. (Pubitemid 351514650)
21. Mata-Marin JA, Gaytan-Martinez J, Grados-Charvarria BH, Fuentes-Allen JL, Arroyo-Anduiza CI, Alfaro-Mejía A,. Correlation between HIV viral load and amino transferases as liver damage markers in HIV infected naïve patients: a concordance cross-sectional study. Virol J 2009; 5: 181.
22. Kovari H, Ledergerber B, Battegay M, et al. Incidence and risk factors for chronic elevations of alanine aminotransferase levels in HIV-infected persons without hepatitis B or C virus co-infection. Clin Infect Dis 2010; 50: 502-511.
23. DallaPiazza M, Amorosa VK, Lacalio R, et al. Prevalence and risk factors for significant liver fibrosis among HIV-monoinfected patients. BMC Infect Dis 2010; 10: 116.
24. Benhamou Y, Di Martino V, Bochet M, et al. Factors affecting liver fibrosis in human immunodeficiency virus- and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. MultivirC Group. Hepatology 2001; 34: 283-287. (Pubitemid 32702341)
25. Macias J, Castellano V, Merchante N, et al. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. AIDS 2004; 18: 767-774. (Pubitemid 38535004)
26. Verma S, Wang CH, Govindarajan S, Kanel G, Squires K, Bonacini M,. Do type and duration of antiretroviral therapy attenuate liver fibrosis in HIV-hepatitis C virus-coinfected patients? Clin Infect Dis 2006; 42: 262-270. (Pubitemid 43054201)
27. Qurishi N, Kreuzberg C, Luchers G, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus co-infection. Lancet 2003; 362: 1708-1713. (Pubitemid 37468321)
28. Soriano V, Puoti M, Garcia-Gasco P, et al. Antiretroviral drugs and liver injury. AIDS 2008; 22: 1-13. (Pubitemid 350301936)
29. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple non-invasive index to predict significant fibrosis in patients with HIV/HCV co-infection. Hepatology 2006; 43: 1317-1325. (Pubitemid 43980111)
30. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology 2007; 46: 32-36. (Pubitemid 47171918)
31. Shire NJ, Rao MB, Succop P, et al. Improving noninvasive methods of assessing liver fibrosis in patients with hepatitis C virus/human immunodeficiency virus co-infection. Clin Gastroenterol Hepatol 2009; 7: 471-480.
32. Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ,. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 7: 1104-1112.
33. Forrester JE, Tucker KL, Gorbach SL,. Dietary intake and body mass index in HIV-positive and HIV-negative drug abusers of Hispanic ethnicity. Public Health Nutr 2004; 7: 863-870. (Pubitemid 39389269)
34. Singer JB, Willett JB,. Applied Longitudinal Data Analysis: Modeling Change and Event Occurrence. New York: Oxford University Press Inc, 2003.
35. Pratt DS, Kaplan MM,. Laboratory tests. In:, Schiff R, Sorrell MF, Maddrey WC, eds. Schiff's Diseases of the Liver, 10th edn. Philadelphia, PA: Lippincott Williams & Wilkins, 2007: 19-60.
36. Blackard JT, Welge JA, Taylor LE, et al. HIV mono-infection is associated with FIB-4-a noninvasive index of liver fibrosis-in women. Clin Infect Dis 2011; 52: 674-680.
37. Babu CK, Suwansrinon K, Bren GD, Badley AD, Rizza SA,. HIV induces TRAIL sensitivity in hepatocytes. PLoS ONE 2009; 4 (2): e4623.
38. Balagopal A, Philp FH, Astemborski J, et al. Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology 2008; 135: 226-233. (Pubitemid 351899010)
39. Thomas DL, Rich JD, Schuman P, et al. Multicenter evaluation of hepatitis C RNA levels among female injection drug users. J Infect Dis 2001; 183: 973-976. (Pubitemid 32207068)
40. Marks KM, Clarke RM, Bussel JB, Talal AH, Glesby MJ,. Risk factors for thrombocytopenia in HIV-infected persons in the era of potent antiretroviral therapy. J Acquir Immune Defic Syndr 2009; 52: 595-599.
41. Ballem PJ, Belzberg A, Devine DV, et al. Kinetic studies of the mechanism of thrombocytopenia in patients with human immunodeficiency virus infection. N Engl J Med 1992; 327: 1779-1784.
42. Guerrero R, Vega GL, Grundy SM, Browning JD,. Ethnic differences in hepatic steatosis: an insulin resistance paradox? Hepatology 2009; 49: 791-801.
43. Day CP, James OFW,. Hepatic steatosis: innocent bystander or guilty party? Hepatology 1998; 27: 1463-1466. (Pubitemid 28264666)
44. Valdez H, Lederman MM,. Cytokines and cytokine therapies in HIV infection. AIDS Clin Rev 1997; 1997-1998: 187-228.